| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Romualdo Barroso-Sousa | Q62743897 |
| Sara M Tolaney | Q90198507 | ||
| P2093 | author name string | Geoffrey I Shapiro | |
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1) | Q24324148 | ||
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors | Q27853037 | ||
| The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study | Q27853110 | ||
| The retinoblastoma protein and cell cycle control | Q27860722 | ||
| Targeting CDK4 and CDK6: From Discovery to Therapy | Q28082912 | ||
| Cancer cell cycles | Q29547756 | ||
| Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer | Q30419997 | ||
| Response assessment criteria for brain metastases: proposal from the RANO group. | Q30969912 | ||
| CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment | Q33419302 | ||
| The history and future of targeting cyclin-dependent kinases in cancer therapy | Q34460347 | ||
| The Role of CDK4/6 Inhibition in Breast Cancer | Q35586728 | ||
| Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors | Q36694995 | ||
| Targeting breast cancer with CDK inhibitors | Q38365261 | ||
| FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer | Q38577772 | ||
| Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind | Q39944735 | ||
| Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft | Q40763120 | ||
| Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors | Q46137197 | ||
| Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation | Q57287362 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 167-173 | |
| P577 | publication date | 2016-06-22 | |
| P1433 | published in | Breast Care | Q15764648 |
| P1476 | title | Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer | |
| P478 | volume | 11 |
| Q99592641 | A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer |
| Q58700136 | A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors |
| Q57163370 | An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer |
| Q33614544 | CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer. |
| Q54977668 | CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer? |
| Q92890459 | CDK4/6 inhibitors in advanced breast cancer, what is beyond? |
| Q38723383 | CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest. |
| Q50045986 | Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. |
| Q39060497 | Cellular senescence in renal ageing and disease |
| Q47406875 | Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling |
| Q58760731 | Cyclin-dependent kinase 4 is a preclinical target for diet-induced obesity |
| Q38662999 | Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib |
| Q47963513 | Discovery and Pharmacological Characterisation of a Novel Series of Highly Selective Inhibitors of Cyclin-Dependent Kinases 4 and 6 as Anticancer Agents. |
| Q49957687 | Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer |
| Q57108908 | Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature |
| Q91692711 | Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials |
| Q47551153 | Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance |
| Q41551635 | Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. |
| Q52579552 | Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma. |
| Q59795283 | Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review |
| Q53685801 | MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer. |
| Q97876301 | MEK blockade overcomes the limited activity of palbociclib in head and neck cancer |
| Q55310990 | Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer. |
| Q37632170 | Progress with palbociclib in breast cancer: latest evidence and clinical considerations |
| Q55353691 | Recent Advances in the Treatment of Breast Cancer. |
| Q47169141 | Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib |
| Q33602076 | Recent advances of highly selective CDK4/6 inhibitors in breast cancer |
| Q38649485 | Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer |
| Q47161171 | Synthesis and Anti-Proliferative Effects of Mono- and Bis-Purinomimetics Targeting Kinases |
| Q64119664 | Targeting stem cells in the realm of drug-resistant breast cancer |
| Q57115037 | Targeting the cell cycle in breast cancer: towards the next phase |
| Q37124719 | The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment |
| Q90396655 | The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer |
| Q91936550 | The emerging role of CDK4/6i in HER2-positive breast cancer |
| Q39218376 | Understanding cell cycle and cell death regulation provides novel weapons against human diseases. |
Search more.